INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A.
PRNewsWire9/24/2026Neutral
CLLS
Cellectis SANASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$144.03M
P/E Ratio
—
EPS
$-0.63
Beta
2.77
52W High
$5.48
52W Low
$1.25
50-Day MA
$2.78
200-Day MA
$3.53
Dividend Yield
—
Profit Margin
-102.30%
Forward P/E
—
PEG Ratio
0.00
About Cellectis SA
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
Fundamentals
| Revenue (TTM) | $63.82M |
| Gross Profit (TTM) | $63.82M |
| EBITDA | $-46.68M |
| Operating Margin | -340.70% |
| Return on Equity | -94.50% |
| Return on Assets | -11.70% |
| Revenue/Share (TTM) | $0.64 |
| Book Value | $0.56 |
| Price-to-Book | 3.85 |
| Price-to-Sales (TTM) | 2.26 |
| EV/Revenue | 1.385 |
| EV/EBITDA | -3.90 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -62.10% |
| Shares Outstanding | $72.72M |
| Float | $48.58M |
| % Insiders | 0.00% |
| % Institutions | 15.36% |
Historical Volatility
HV 10-Day
27.02%
HV 20-Day
60.92%
HV 30-Day
60.79%
HV 60-Day
59.05%
HV Rank
30.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($5.33 target)
2
Strong Buy2
Buy1
HoldLatest News
CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC
ATLANTA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) complied with federal securities laws. On September 14, 2026, Cellectis announced that it will “exit the development of lasme-cel and eti-cel[.]” On this news, the price of the Company's stock dropped.
GlobeNewsWire9/17/2026Neutral
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CELLECTIS S.A. (CLLS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On Septem.
Business Wire9/17/2026Neutral
Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Transcript
Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Transcript
Seeking Alpha9/14/2026Neutral
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.
GlobeNewsWire9/14/2026Neutral
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.
GlobeNewsWire9/11/2026Neutral
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
GlobeNewsWire9/3/2026Neutral
Cellectis Reports Financial Results for the Second Quarter 2026
GlobeNewsWire8/6/2026Neutral
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
GlobeNewsWire8/5/2026Neutral
Cellectis to Report Second Quarter Financial Results on August 6, 2026
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.
GlobeNewsWire7/30/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLLS and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026